X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, PeptiDream will use its proprietary Peptide Discovery Platform System (“PDPS”) technology to discover, optimize, and develop macrocyclic peptide candidates for use as peptide-RI drug conjugates against targets of interest to Genentech.
Lead Product(s): Peptide-radioisotope Drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Genentech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 19, 2023
Details:
The collaboration aims to discover novel protein degraders by leveraging PeptiDream's PDPS (Peptide Discovery Platform System) technology, for two targets and Astellas will have the option to select up to three additional targets to be included in the collaboration.
Lead Product(s): Protein Degrader Drug
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $749.9 million Upfront Cash: $21.2 million
Deal Type: Collaboration July 25, 2023
Details:
AZP-3813, a peptide GHR antagonist, is being developed as a potential treatment for acromegaly to be used in combination with somatostatin analogues (SSAs) for patients who do not adequately respond to SSAs alone.
Lead Product(s): AZP-3813
Therapeutic Area: Endocrinology Product Name: AZP-3813
Highest Development Status: Phase IProduct Type: Peptide
Recipient: Amolyt Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
Candidate was discovered using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) and demonstrated potent and selective GPC3 binding, rapid cellular internalization and sustained tumor specific uptake and anti-tumor efficacy in pre-clinical models.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
Under the agreement, PeptiDream will provide peptide candidates identified from PeptiDream’s proprietary Peptide Discovery Platform System (“PDPS”) technology for use as PDCs against targets of interest to MSD.
Lead Product(s): Peptide-drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Peptide
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: $2,100.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 27, 2022
Details:
Under the agreement, PeptiDream will utilize its proprietary Peptide Discovery Platform System (“PDPS”) technology to identify high affinity macrocyclic peptide ligands to Lilly-elected targets of interest for the discovery and development of novel peptide drug conjugates.
Lead Product(s): Peptide-drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Peptide
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,235.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 26, 2022
Details:
Extension of the research collaboration term to allow for additional peptide-RI conjugate discovery and development programs. RayzeBio grants PeptiDream an option to attain development and commercialization rights in Japan to the joint peptide-RI programs.
Lead Product(s): Peptide-radioisotope Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: RayzeBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 09, 2022
Details:
The new collaboration expands the use of the TfR1 binding peptide ligands for CNS targets associated with neurodegeneration allowing Takeda to conjugate the peptides with therapeutic cargoes optimized to cross the blood-brain barrier (BBB).
Lead Product(s): Peptide-drug Conjugates
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $3,500.0 million Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration July 29, 2021
Details:
PeptiDream will select, optimize, and synthesize peptides for each receptor. Alnylam will then generate peptide-siRNA conjugates and perform in vitro and in vivo studies to support final peptide selection.
Lead Product(s): Peptide-siRNA Conjugates
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Peptide
Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals
Deal Size: $2,200.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 29, 2021
Details:
The new company, to be called PeptiAID Inc, will research and develop peptide therapeutics for the current SARS-CoV-2 virus and potential future coronavirus outbreaks.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Peptide
Partner/Sponsor/Collaborator: Fujitsu
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
